DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
SGN-30 is an investigational drug.
There have been 71 clinical trials for SGN-30. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Hodgkin Disease. The leading clinical trial sponsors are Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., and Genentech, Inc.
There are six US patents protecting this investigational drug and forty-seven international patents.
Recent Clinical Trials for SGN-30
|A Study of SGN-CD228A in Advanced Solid Tumors||Seattle Genetics, Inc.||Phase 1|
|A Safety Study of SGN-CD47M in Patients With Solid Tumors||Seattle Genetics, Inc.||Phase 1|
|BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)||Takeda||Phase 1/Phase 2|
Top disease conditions for SGN-30
Top clinical trial sponsors for SGN-30
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SGN-30||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|SGN-30||Start Trial||Methods for glycoprotein remodeling using endoglycosidase mutants||CHO Pharma Inc. (Taipei, TW) Academia Sinica (Taipei, TW)||Start Trial|
|SGN-30||Start Trial||Compositions and methods for cancer immunotherapy||Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP)||Start Trial|
|SGN-30||Start Trial||Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof||UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|